S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why Your IRA Could Crash on June 16th (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why Your IRA Could Crash on June 16th (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why Your IRA Could Crash on June 16th (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why Your IRA Could Crash on June 16th (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
NASDAQ:RDNT

RadNet (RDNT) Competitors

$32.10
+0.44 (+1.39%)
(As of 06/9/2023 ET)
Compare
Today's Range
$30.22
$32.37
50-Day Range
$25.00
$32.10
52-Week Range
$12.03
$32.37
Volume
755,407 shs
Average Volume
338,171 shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

RDNT vs. VCYT, FLGT, VRDN, PROG, CDNA, GH, NTRA, PCRX, ATEC, and FGEN

Should you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Veracyte (VCYT), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), Progenity (PROG), CareDx (CDNA), Guardant Health (GH), Natera (NTRA), Pacira BioSciences (PCRX), Alphatec (ATEC), and FibroGen (FGEN). These companies are all part of the "medical" sector.

RadNet vs.

RadNet (NASDAQ:RDNT) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.

In the previous week, RadNet had 4 more articles in the media than Veracyte. MarketBeat recorded 8 mentions for RadNet and 4 mentions for Veracyte. Veracyte's average media sentiment score of 0.76 beat RadNet's score of -0.12 indicating that Veracyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RadNet
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veracyte
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

RadNet currently has a consensus price target of $30.00, indicating a potential downside of 6.54%. Veracyte has a consensus price target of $30.20, indicating a potential upside of 16.87%. Given Veracyte's higher probable upside, analysts plainly believe Veracyte is more favorable than RadNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RadNet
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Veracyte
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

RadNet has higher revenue and earnings than Veracyte. RadNet is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RadNet$1.43 billion1.31$10.65 million-$0.24-133.74
Veracyte$296.54 million6.31-$36.56 million-$0.41-63.02

68.3% of RadNet shares are held by institutional investors. 4.4% of RadNet shares are held by insiders. Comparatively, 2.9% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

RadNet has a net margin of -0.90% compared to Veracyte's net margin of -9.70%. RadNet's return on equity of 3.28% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
RadNet -0.90% 3.28% 0.67%
Veracyte -9.70% -2.83% -2.63%

RadNet has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Veracyte received 88 more outperform votes than RadNet when rated by MarketBeat users. Likewise, 73.14% of users gave Veracyte an outperform vote while only 67.20% of users gave RadNet an outperform vote.

CompanyUnderperformOutperform
RadNetOutperform Votes
334
67.20%
Underperform Votes
163
32.80%
VeracyteOutperform Votes
422
73.14%
Underperform Votes
155
26.86%

Summary

RadNet beats Veracyte on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDNT vs. The Competition

MetricRadNetMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$1.87B$1.84B$4.58B$6.28B
Dividend YieldN/A1.81%2.26%6.27%
P/E Ratio-133.745.0292.9512.78
Price / Sales1.3165.653,376.9090.51
Price / Cash8.947.1394.08115.16
Price / Book3.754.104.715.30
Net Income$10.65M-$115.36M$117.47M$193.31M
7 Day Performance5.66%-1.51%0.81%1.29%
1 Month Performance13.59%-3.89%1.01%4.61%
1 Year Performance67.62%17.02%19.11%5.86%

RadNet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
1.6932 of 5 stars
$25.81
-0.4%
$30.20
+17.0%
+47.9%$1.87B$296.54M-62.95761
FLGT
Fulgent Genetics
2.2343 of 5 stars
$39.75
+1.7%
$42.33
+6.5%
-25.3%$1.18B$618.97M-44.661,012Positive News
VRDN
Viridian Therapeutics
1.8732 of 5 stars
$24.99
+0.5%
$45.00
+80.1%
+126.8%$1.08B$1.77M-5.3650
PROG
Progenity
0 of 5 stars
$4.58
+7.5%
N/A+680.3%$843.63M$1.25M-1.63124Gap Up
CDNA
CareDx
1.9436 of 5 stars
$8.45
+5.9%
$16.00
+89.3%
-68.0%$454.53M$321.79M-5.60633
GH
Guardant Health
2.3461 of 5 stars
$32.67
+0.9%
$56.27
+72.2%
-15.8%$3.36B$449.54M-5.031,793
NTRA
Natera
2.079 of 5 stars
$48.33
+1.2%
$73.78
+52.7%
+35.4%$5.52B$820.22M-9.033,018Insider Selling
PCRX
Pacira BioSciences
2.0763 of 5 stars
$39.08
+1.4%
$62.73
+60.5%
-36.4%$1.80B$666.82M-144.74697Insider Selling
News Coverage
ATEC
Alphatec
1.7203 of 5 stars
$15.34
-0.3%
$16.25
+5.9%
+110.0%$1.82B$389.04M-10.65561Analyst Downgrade
FGEN
FibroGen
2.0096 of 5 stars
$18.71
-2.5%
$24.83
+32.7%
+70.0%$1.83B$140.73M-5.72566Insider Selling
Options Volume
News Coverage

Related Companies and Tools

This page (NASDAQ:RDNT) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -